Alvogen And Pfenex Broaden Teriparatide Collaboration
Executive Summary
Alvogen and Pfenex have agreed to expand their existing US collaboration on Pfenex’ PF708 teriparatide candidate to also encompass the EU, certain MENA countries and other international markets.
You may also be interested in...
Ligand Snaps Up Pfenex For Half A Billion
Ligand Pharmaceuticals has struck a deal to acquire Pfenex in a transaction valued at up to $516m.
Kamada Licenses Alvotech Biosimilars In Israel
Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.
Alvogen Strikes Deals For Pfenex’ Teriparatide
Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.